Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations

Aoife M. Rodgers, Aaron J. Courtenay, Ryan F. Donnelly

Research output: Contribution to journalEditorial

11 Citations (Scopus)

Abstract

Dissolving microneedle (DMN) arrays are minimally invasive
devises that consist of a series of microscopic needles on a base
support. Upon insertion into the skin, the needles dissolve depositing
their payload (Figure 1(A–C)) [1]. DMN have received substantial
interest for intradermal vaccination due to their ease of use
and possibility for self-administration. DMN research is close to
commercialization. However, moving forward, there remain a
number of concerns which warrant investigation. Herein, such
considerations are discussed with a specific focus on the key
challenges for DMN industrialization being highlighted.
Original languageEnglish
Pages (from-to)1039-1043
Number of pages4
JournalExpert Opinion on Drug Delivery
Volume15
Issue number11
Early online date11 Sep 2018
DOIs
Publication statusE-pub ahead of print - 11 Sep 2018

Keywords

  • Dissolving
  • microneedle
  • vaccination
  • immunization
  • scale-up

Cite this

@article{ae9fc86c63d54efdbb014a9575ec662d,
title = "Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations",
abstract = "Dissolving microneedle (DMN) arrays are minimally invasivedevises that consist of a series of microscopic needles on a basesupport. Upon insertion into the skin, the needles dissolve depositingtheir payload (Figure 1(A–C)) [1]. DMN have received substantialinterest for intradermal vaccination due to their ease of useand possibility for self-administration. DMN research is close tocommercialization. However, moving forward, there remain anumber of concerns which warrant investigation. Herein, suchconsiderations are discussed with a specific focus on the keychallenges for DMN industrialization being highlighted.",
keywords = "Dissolving, microneedle, vaccination, immunization, scale-up",
author = "Rodgers, {Aoife M.} and Courtenay, {Aaron J.} and Donnelly, {Ryan F.}",
year = "2018",
month = "9",
day = "11",
doi = "10.1080/17425247.2018.1522301",
language = "English",
volume = "15",
pages = "1039--1043",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
number = "11",

}

Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations. / Rodgers, Aoife M.; Courtenay, Aaron J.; Donnelly, Ryan F.

In: Expert Opinion on Drug Delivery, Vol. 15, No. 11, 11.09.2018, p. 1039-1043.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations

AU - Rodgers, Aoife M.

AU - Courtenay, Aaron J.

AU - Donnelly, Ryan F.

PY - 2018/9/11

Y1 - 2018/9/11

N2 - Dissolving microneedle (DMN) arrays are minimally invasivedevises that consist of a series of microscopic needles on a basesupport. Upon insertion into the skin, the needles dissolve depositingtheir payload (Figure 1(A–C)) [1]. DMN have received substantialinterest for intradermal vaccination due to their ease of useand possibility for self-administration. DMN research is close tocommercialization. However, moving forward, there remain anumber of concerns which warrant investigation. Herein, suchconsiderations are discussed with a specific focus on the keychallenges for DMN industrialization being highlighted.

AB - Dissolving microneedle (DMN) arrays are minimally invasivedevises that consist of a series of microscopic needles on a basesupport. Upon insertion into the skin, the needles dissolve depositingtheir payload (Figure 1(A–C)) [1]. DMN have received substantialinterest for intradermal vaccination due to their ease of useand possibility for self-administration. DMN research is close tocommercialization. However, moving forward, there remain anumber of concerns which warrant investigation. Herein, suchconsiderations are discussed with a specific focus on the keychallenges for DMN industrialization being highlighted.

KW - Dissolving

KW - microneedle

KW - vaccination

KW - immunization

KW - scale-up

U2 - 10.1080/17425247.2018.1522301

DO - 10.1080/17425247.2018.1522301

M3 - Editorial

VL - 15

SP - 1039

EP - 1043

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 11

ER -